Moncyte Health is a technology company.
Moncyte Health has raised $1.0M across 1 funding round.
Moncyte Health has raised $1.0M in total across 1 funding round.
Moncyte Health is a biotech spinout from the University of Helsinki developing a patented diagnostic test that analyzes cellular mechanisms in white blood cells to personalize cholesterol-lowering therapies, addressing high cholesterol—a risk factor affecting over 1.5 billion people worldwide.[1][2][3] The MONCYTE Test serves clinicians, health centers, clinical studies, and pharmaceutical companies by predicting patient responses to drugs like statins, ezetimibe, bempedoic acid, or PCSK9 inhibitors, reducing trial-and-error, accelerating target cholesterol achievement, and lowering cardiovascular risks such as heart attacks and strokes.[2][3][4][6] Its growth includes a €1 million seed round from investors like Almaral and Athensmed, and selection for a €7.2 million Horizon Europe FH-EARLY project on familial hypercholesterolemia (FH), signaling strong early momentum in precision medicine.[3][5]
Moncyte Health emerged from basic cell biology research at the University of Helsinki on cholesterol transport and processing in human cells, particularly monocytes involved in plaque formation and inflammation.[1][2][4] Co-founders Tamara Alagirova (CEO), with expertise in biotech commercialization, and Simon Pfisterer PhD (CSO), a cellular mechanisms specialist from the university, transformed this into a spinout company via a Business Finland-funded project that ended with patent filing and company formation.[1][2][4] Pivotal early traction came from Helsinki Innovation Services' support, validating the technology's potential to create a new diagnostic market segment, followed by €1 million seed funding in 2023 to advance clinical development.[1][3]
Moncyte Health rides the precision medicine wave in cardiovascular disease (CVD), the leading global killer, where high cholesterol drives atherosclerosis and only half of FH cases are genetically identified, leaving gaps in early intervention.[3][5] Timing aligns with rising demand for cellular diagnostics amid statin limitations (many patients fail targets) and booming lipid-lowering pipelines (e.g., PCSK9i), fueled by market forces like aging populations and post-pandemic CVD focus.[1][3][4] It influences the ecosystem by enabling pharma efficiency in trials, supporting EU-funded initiatives like FH-EARLY for novel pathways, and pioneering a competition-light segment for centralized testing services, potentially expanding to other metabolic disorders.[4][5][6]
Moncyte Health is poised to scale its test commercially via centralized labs, deepen FH-EARLY integration for validation/data, and partner with pharma for trial readouts, targeting Europe/US markets where cholesterol drugs dominate prescriptions.[1][3][4] Trends like AI-multiomics in CVD risk and personalized lipid therapies will amplify its edge, evolving it from spinout to key player in preventing 1.5B+ at-risk lives through faster, effective interventions—building directly on its cellular innovation to redefine high-cholesterol management.[2][5][6]
Moncyte Health has raised $1.0M in total across 1 funding round.
Moncyte Health's investors include Inventure, Revalence Ventures, Spintop Ventures.
Moncyte Health has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $1.0M Seed | Inventure, Revalence Ventures, Spintop Ventures |